Pfizer has submitted an application to the US Food and Drug Administration (FDA) for Emergency Use Authorisation (EUA) of its investigational oral antiviral drug, Paxlovid (PF-07321332; ritonavir).
Pfizer has sought Emergency Use Authorization (EUA) from the US Food and Drug Administration (FDA) for its experimental oral antiviral pill, Paxlovid (PF-07321332; ritonavir), to treat individuals with mild-to-moderate Covid-19.
Pfizer has announced its investigational novel COVID-19 oral antiviral candidate, Paxlovid™, significantly reduced hospitalisation and death, based on an interim analysis of the Phase II/III EPIC-HR randomised...